L'Oréal partners with bacteriophage company Micreos for skin microbiome applications

November 12, 2020
Accelerating Materials Innovation More...
Average importance

Through this licensing agreement, L'Oréal will gain access to Micreos' endolysin technology for cosmetic and skin care applications. Micreos develops the "Staphefekt" endolysin, which is a phage enzyme that selectively kills Staphylococcus aureus bacteria. The company has already commercialized its endolysin-containing Gladskin product for a number of skin conditions. While several players in the skin microbiome space focus on the use of probiotics, this partnership will help L'Oréal explore the applicability of phage-based solutions for skin care applications. As the skin microbiome space evolves further, we expect to see more players in the cosmetics industry value chain getting involved through such partnerships for product development.

For the original news article, click here .

Further Reading

Skin Microbiome

Technology | June 08, 2020

Modulation of microorganisms that reside on the skin. Not part of subscription

Geltor launches animal-free elastin for skin care market

News Commentary | April 15, 2020

The company's new product Elastapure containing human elastin targets replacing animal‑derived elastin for skin care applications. Geltor focuses on both cosmetics and food applications; however, its offerings for cosmetics are slightly more advanced. It currently has three commercialized ... Not part of subscription

Industry Event Recap: Key takeaways from Probiota 2021

Analyst Insight | February 25, 2021

This year's Probiota Europe event took place virtually and brought together global experts from industry and academia to discuss the present and the future of microbiome modulation through ‑biotics for consumer health. Lux presented at the event and participated in a panel discussion about the ... Not part of subscription